🤔 Empagliflozin in acute decompensated heart failure
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (Voors, Nature Medicine 2023)
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (Voors, Nature Medicine 2023)
TenTweetNephJC on X. Natriuresis guidance for intensification of diuretics is one strategy to PUSH decongestion in patient’s with acute heart failure.
Does Torsemide lower all cause mortality compared to furosemide for heart failure patients post-hospitalization? Cristina Popa elaborates, visually!
The ADVOR trial (adding acetazolamide in acute heart failure) is covered by #TenTweetNephJC
If you missed out of the great #NephJC chat this week you can catch-up with our rapid 10 tweet summary.
This instalment of #TenTweetNephJC - the quickest way to stay up to date - recaps the recent NephJC chat on a mechanistic study investigating diuretic resistance, check it out at the link….
OIn order to understand the significance of this week’s NephJC you should have more than a passing familiarity with DAPA-HF one of the foundational SGLT2i studies. To help you brush up here is a superior visual abstract by Sudha Mannemuddhu